Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADR-002K in Heart Failure Patients With Ischemic Heart Disease Undergoing CABG
NCT07192211Phase 2Recruiting
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Sep 2028
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ADR-002K in chronic heart failure (CHF) and ischemic heart disease (IHD) (2 arms), sponsored by Rohto Pharmaceutical Co., Ltd. Primary endpoint: Time to the first occurrence of the cardiovascular events at 2 years. Started Apr 2026; status: recruiting.
02
Drugs
ADR-002K
03
Conditions
chronic heart failure (CHF)ischemic heart disease (IHD)
Beyond the preview
Go deeper on NCT07192211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192211.